CAPRELSA (Genzyme Corporation)


Welcome to the PulseAid listing for the CAPRELSA drug offered from Genzyme Corporation. This Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Organic Cation Transporter 2 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Genzyme Corporation
NON-PROPRIETARY NAME: Vandetanib
SUBSTANCE NAME: VANDETANIB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Organic Cation Transporter 2 Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2011-07-25
END MARKETING DATE: 0000-00-00


CAPRELSA HUMAN PRESCRIPTION DRUG Details:

Item DescriptionCAPRELSA from Genzyme Corporation
LABELER NAME: Genzyme Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 100(mg/1)
START MARKETING DATE: 2011-07-25
END MARKETING DATE: 0000-00-00
PRODUCT ID: 58468-7820_5da353d0-df87-4359-a92b-df8811769e55
PRODUCT NDC: 58468-7820
APPLICATION NUMBER: NDA022405

Other VANDETANIB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AstraZeneca Pharmaceuticals LPCAPRELSA
Genzyme CorporationCAPRELSA